Document-Centric Operations Can't Keep Up With Modern…
Rising amendment rates, longer startup times, and regulatory shifts are exposing the limits of paper-era workflows in today's data-intensive trials. · Most…
Trial Watch posts – September 2026
Public Trial Watch posts from September 2026, newest first. Each heading links to the post.
Phase 2 Protocol Design: Why Getting It Right Matters More…
Poor protocol construction is driving longer timelines and compromising Phase 3 readiness as amendment cycles stretch to 260 days. · Phase 2 represents the…
France Is Europe’s Oncology Capital for Clinical Trials
Oncology depth, national CHU networks, ANSM review pathways and Health Innovation 2030 keep France central to European clinical research. · France is one of…
Protocol Amendments: The 3-Month Timeline Risk Sites Need…
76% of protocols now require at least one amendment, adding unplanned months and significant cost to trial completion. · Most clinical trial protocols change…
Trial Watch 16: Immunology and respiratory programs move…
Edition 16 shows Phase 3 activity across atopic dermatitis, respiratory disease and immune mediated conditions. · Immunology and respiratory together…
Why Your Site's Investigator Brochure Is More Than Just…
A poorly maintained IB directly affects patient safety reporting, and recent inspections found critical failures at eight organizations. · The Investigator…
Germany Remains Europe’s Scientific Backbone for Clinical…
Deep university hospital networks, regulatory reform and world class research infrastructure keep Germany central to European clinical development. · Germany…
FHIR Plus LLMs: A Technical Path to Faster Patient…
How standardized EHR data and AI-driven eligibility parsing are addressing the structural bottlenecks slowing trial enrollment. · Most recruitment delays…
Trial Watch: Edition 16
Where conviction is building in clinical development, in real time. · Trial Watch Edition 16 captures high signal clinical development activity from August 16…
How CDISC Standards Shape AI Document Generation in…
Understanding the regulatory constraints and opportunities when AI tools generate protocols, CSRs, and datasets · AI-generated clinical documents promise…
ICH E6(R3) Moves IB Requirements to Appendix A: What Sites…
New GCP guideline repositions the Investigator's Brochure as an integral framework component, not a standalone admin document. · ICH E6(R3) formally relocated…
Trial Watch 15: Oncology studies move toward sharper…
Edition 15 highlights oncology programs using targeted trial designs, specific patient groups and late stage clinical testing. · Oncology contributes five…
AI in Pharma R&D: What the Evidence Actually Shows for…
From the first AI-assisted Phase IIa result to enrollment gains and FDA guidance, here's where the data is strong and where it's still emerging. · In June…
Trial Watch 15: Immunology programs enter a more…
Two atopic dermatitis studies and one VEXAS syndrome program show how immunology development is broadening across common and rare disease settings. ·…